Nerve conduction studies support the classification of SARS‐CoV‐2 associated Guillain‐Barre subtypes

Response to “Nerve conduction studies support the classification of SARSCoV‐2 associated Guillain‐Barre subtypes”

“…Dear Editor, We read with interest the comments made by Finsterer et al 1 on our previously published case report "Guillain-Barré syndrome after coronavirus disease 2019 vaccine: A temporal association". 2 We understand that the comments made are interesting points of discussion.…”

“…First, due to the time the article was written, in which there were not as many cases reported in the literature as currently, as correctly described in the letter “In a recent review of the neurological side effects of SARS‐CoV‐2 vaccines, 300 cases of SC2VaG were described”. 1 Second, due to limited diagnostic resources in the case, a public hospital in southern Brazil. The absence of diagnostic tests, such as those mentioned by Finsterer et al (electroneuromyography, investigation of cytokines, chemokines and glial markers in the CSF), are factors that must be highlighted before defining the causality of the association.…”